Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $14.00 Average PT from Analysts

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $14.00.

A number of analysts have recently commented on KLRS shares. Citizens Jmp started coverage on shares of Kalaris Therapeutics in a report on Monday, November 3rd. They set a “market outperform” rating and a $20.00 target price for the company. Chardan Capital initiated coverage on shares of Kalaris Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Finally, Wall Street Zen cut Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st.

Kalaris Therapeutics Stock Performance

NASDAQ:KLRS opened at $8.65 on Wednesday. The stock has a 50-day simple moving average of $9.02 and a 200 day simple moving average of $6.14. Kalaris Therapeutics has a 52-week low of $2.14 and a 52-week high of $12.90. The company has a market cap of $161.76 million, a PE ratio of -2.29 and a beta of -0.09.

Kalaris Therapeutics (NASDAQ:KLRS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02.

Hedge Funds Weigh In On Kalaris Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Nano Cap New Millennium Growth Fund L P bought a new stake in Kalaris Therapeutics during the fourth quarter worth $34,000. Johnson Financial Group Inc. acquired a new position in shares of Kalaris Therapeutics during the 3rd quarter worth about $58,000. Keel Point LLC bought a new stake in shares of Kalaris Therapeutics in the 4th quarter valued at about $86,000. Walleye Capital LLC bought a new stake in shares of Kalaris Therapeutics in the 4th quarter valued at about $95,000. Finally, Simplify Asset Management Inc. acquired a new stake in Kalaris Therapeutics in the 4th quarter valued at about $169,000. 66.05% of the stock is owned by institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.